Research programme: calcium channel and sodium channel antagonists - Anabios Corporation

Drug Profile

Research programme: calcium channel and sodium channel antagonists - Anabios Corporation

Alternative Names: N-type CCB; N/T-Type CCB; NP-A; T-type CCB; Z-212

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuromed Pharmaceuticals
  • Developer Hydra Biosciences; Neuromed Pharmaceuticals
  • Class Analgesics; Small molecules
  • Mechanism of Action N type calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 15 Jul 2014 Zalicus has merged with EPIRUS Biopharmaceuticals
  • 18 Jun 2014 Sodium channel modulator programme licensed to AnaBios Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top